Platelet Rich Plasma (PRP) Market – By Type [Pure Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet Rich Plasmas (L-PRP)] Origin (Autologous, Allogenic), Application (Orthopedics & Sports Medicine, Cosmetic Surgery), End-use, Forecast 2024 – 2032

Platelet Rich Plasma Market Size

Platelet Rich Plasma Market size was valued at USD 479.6 million in 2023 and is anticipated to witness growth at a CAGR of 10.6% between 2024 and 2032. The increasing prevalence of chronic and lifestyle-related diseases, such as orthopedic conditions, sports injuries, and cardiovascular diseases, has heightened the demand for advanced therapeutic options like PRP.
 

Additionally, the rising number of cosmetic and aesthetic procedures, particularly in dermatology, where PRP is used for skin rejuvenation and hair loss treatments, significantly boosts market growth. Furthermore, supportive government initiatives and an increasing number of clinical trials demonstrating the efficacy and safety of PRP therapy contribute to its expanding adoption across various medical fields. The increasing demand for PRP therapy drives the growth of PRP systems market.
 

Platelet Rich Plasma (PRP) systems or kits are medical devices used to prepare and administer Platelet Rich Plasma (PRP) from blood. Platelet-Rich Plasma (PRP) is a concentration of blood platelets, containing a higher number of platelets than what is typically found in blood. The PRP kits/systems are designed to separate and concentrate platelets from the patient's blood to produce PRP for therapeutic use. PRP plays a crucial role in healing and tissue regeneration by releasing growth factors that stimulate cell proliferation, tissue repair, and collagen production.
 

Platelet Rich Plasma Market Trends

• The growing cosmetic and aesthetic applications of platelet-rich plasma (PRP) therapy are significantly driving the PRP market.
   
• Platelet-rich plasma (PRP) has become increasingly popular for cosmetic procedures in recent years, with the American Society of Plastic Surgeons reporting a 25% increase in cosmetic PRP use between 2015 and 2019.
   
• PRP is increasingly sought after for its rejuvenation characteristics, providing a non-surgical alternative for various aesthetic treatments. It is widely used for skin revitalization, reducing wrinkles, fine lines, and scars, as well as for hair restoration.
   
• Additionally, the rising demand for minimally invasive cosmetic procedures, driven by consumer desire for youthful appearance and natural results, further propels the market.
   
• Moreover, increasing awareness of PRP's effectiveness in enhancing skin texture and tone, combined with its safety profile and minimal downtime, has led to a surge in its adoption in dermatology and aesthetic clinics, thereby boosting the overall PRP market growth.
   

Platelet Rich Plasma Market Analysis

Based on type, the market is segmented into pure platelet-rich plasma (P-PRP), leukocyte- and platelet rich plasmas (L-PRP), and other types. The pure platelet-rich plasma (P-PRP) segment dominated the market in 2023 and accounted for USD 211.1 million.
 

• High segmental growth can be attributed to its extensive application in various medical and aesthetic procedures. P-PRP, known for its high concentration of platelets devoid of white blood cells and erythrocytes, is particularly favored for its efficacy in enhancing tissue regeneration and healing processes.
   
• The segment's dominance is further driven by advancements in PRP preparation techniques, ensuring higher purity and consistency, which in turn boosts patient outcomes and satisfaction.
   
• Additionally, increasing awareness and acceptance among medical professionals and patients alike contribute to the segment's robust market position.
   

 Based on origin, the PRP market is segmented into autologous, allogenic, and homologous. The autologous segment held a market share of 81% in 2023.
 

• The autologous segment holds a significant market share in the platelet rich plasma (PRP) market due to its inherent advantages of safety, efficacy, and reduced risk of immunogenic reactions.
   
• Autologous PRP is derived from the patient's own blood, minimizing the likelihood of adverse reactions and transmission of diseases, which are common concerns with allogenic PRP.
   
• Additionally, wide applicability of autologous PRP in treating a range of conditions, including musculoskeletal injuries, chronic wounds, and cosmetic procedures such as hair restoration and skin rejuvenation, further enhances its adoption.
   

Based on application, the platelet rich plasma market is segmented into orthopedics & sports medicine, cosmetic surgery and dermatology, neurology, cardiology, ophthalmology, and other applications. The orthopedics & sports medicine segment dominated the market in 2023 and is anticipated to grow at a CAGR of 10.3% between 2024 - 2032.
 

• Platelet-rich plasma (PRP) has become increasingly popular in orthopedics and sports medicine as a minimally invasive treatment for musculoskeletal injuries. Its wide application in treating musculoskeletal conditions, including tendon injuries, ligament sprains, and osteoarthritis is driving the market growth.
   
• Additionally, rising incidence of sports injuries, combined with an increasing number of individuals engaging in physical activities, has further driven the demand for PRP treatments.
   
• Furthermore, advancements in PRP preparation techniques and the growing body of clinical evidence supporting its efficacy have bolstered its adoption in orthopedic and sports medicine practices.
   

Based on end-use, the platelet rich plasma market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to reach USD 480.7 million by 2032.
 

• Hospitals are equipped with state-of-the-art facilities and a multidisciplinary approach that supports the integration of PRP therapy into various medical specialties such as orthopedics, dermatology, and sports medicine.
   
• These facilities often have the infrastructure required for PRP preparation, ensuring quality and safety standards are met.
   
• Moreover, hospitals attract a wide range of patients seeking advanced therapeutic options, contributing to the robust demand for PRP treatments.
   

North America platelet rich plasma market was valued at USD 167.7 million in 2023 and is anticipated to reach USD 395.4 million by 2032.
 

• North America commands a significant share of the platelet-rich plasma (PRP) market, driven by robust healthcare infrastructure, advanced medical research facilities, and high adoption rates of regenerative medicine technologies.
   
• The region's dominance is further bolstered by substantial investments in biotechnology and healthcare innovations, fostering the development and commercialization of PRP therapies.
   

The U.S. PRP market is anticipated to grow at a CAGR of 10.1% between 2024 - 2032.
 

• In the U.S., robust healthcare infrastructure supports widespread adoption of PRP procedures, driven by increasing awareness among patients and healthcare providers about its regenerative potential.
   
• Moreover, ongoing advancements in PRP preparation devices contribute to the market's growth, ensuring efficient and standardized PRP processing.
   
• Additionally, favorable reimbursement policies bolster its uptake, positioning the U.S. as a leader in advancing PRP therapies for both therapeutic and aesthetic purposes.
   

Germany is anticipated to witness robust growth in the platelet rich plasma market.
 

• Germany's strong focus on research and development in the healthcare sector has led to the introduction of innovative treatment options, thereby boosting market growth.
   
• Moreover, the presence of leading pharmaceutical companies and healthcare institutions in Germany is fostering collaboration and driving advancements in platelet rich plasma (PRP), position the country as a key growth market in this sector.
   

Asia Pacific region will exhibit high significant growth of 11% over the forecast period. The regional market size is expected to reach USD 297.7 million by end of the forecast period.
 

• Increasing awareness about regenerative medicine and non-surgical treatment options has spurred demand for PRP therapies in the region.
   
• Moreover, advancements in healthcare infrastructure and rising healthcare expenditure have facilitated greater accessibility to PRP treatments in countries like China, India, and Japan.
   
• Additionally, the region benefits from a growing elderly population prone to orthopedic and musculoskeletal conditions, further boosting the adoption of PRP therapies for pain management and tissue regeneration.
   
• These factors collectively contribute to the burgeoning PRP market in the Asia Pacific, positioning it as a pivotal region for future growth and innovation in regenerative therapies.
   

Platelet Rich Plasma Market Share

The platelet-rich plasma industry is characterized by a competitive landscape shaped by a mix of established players and emerging entrants striving to capitalize on the growing demand for regenerative medicine solutions. Key players such as Harvest Technologies (Terumo BCT), Arthrex Inc., and DePuy Synthes (Johnson & Johnson) dominate the market with their extensive product portfolios and strong distribution networks. The competitive dynamics are further fuelled by strategic partnerships, mergers, and acquisitions aimed at expanding market presence and accelerating product development cycles in this rapidly evolving sector.
 

Platelet Rich Plasma Market Companies

Prominent players operating in the platelet rich plasma industry include:

• Arthrex Inc.
• APEX Biologix
• Celling Biosciences, Inc.
• DePuy Synthes (Johnson & Johnson)
• Dr. PRP USA LLC
• EmCyte Corporation
• Exactech, Inc.
• Glofinn Oy
• Isto Biologics
• Juventix Regenerative Medical, LLC.
• Regen Lab SA
• Terumo BCT, Inc.
• ThermoGenesis Holdings Inc.
• Vivostat A/S
   

Platelet Rich Plasma Industry News:

• In March 2023, Arthrex received Food and Drug Administration (FDA) approval to conduct an Investigational Device Exemption (IDE) to study the effects of treating symptomatic osteoarthritis (OA) of the knee using its autologous conditioned plasma (ACP) Max PRP system, which provides concentrated platelets and growth factors from platelet-rich plasma (PRP). This helped the company differentiate its product in the market.
   
• In February 2020, EmCyte Corporation, received FDA 510(k) clearance for its PurePRP Supraphysiologic Concentrating System for platelet rich plasma. This helped the company market its product in the U.S.
   

The platelet rich plasma market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Pure platelet-rich plasma (P-PRP)
• Leukocyte- and platelet rich plasma (L-PRP)
• Other types

Market, By Origin

• Autologous
• Allogenic
• Homologous

Market, By Application

• Orthopedics & sports medicine
• Cosmetic surgery and dermatology
• Neurology
• Cardiology
• Ophthalmology
• Other applications

Market, By End-use

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa